B
BioMedPartners
Venture CapitalActiveBioMedPartners is one of the leading European venture capital firms.
70
Investments
6
Exits
$700M
AUM
8.6%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for BioMedPartners.
Investment Thesis & Strategy
BioMedPartners invests in various stages of biotech, fintech, and venture capital companies, focusing on leading European ventures.
Investment Activity
Deals per year over the last 19 years
1
20000
20010
20020
20031
20040
20051
20062
20071
20080
20090
20100
20110
20121
20131
20140
20152
20160
20171
2018Portfolio Companies
Selected investments from their portfolio of 70 companies
A
Actelion
Biotech · Growth, 0
N
Neuronyx
Biotech · Series A, 2018
T
T3 Pharma
Biotech · Series A, 2016
I
Inositec
Biotech · Series A, 2016
B
BioVersys
Biotech · Series A, 2014
O
ObsEva
Biotech · Growth, 2013
A
AM Pharma
Biotech · Growth, 2008
G
GlycoVaxyn
Biotech · Growth, 2007
E
ESBATech
Biotech · Growth, 2007
N
NovImmune
Biotech · Growth, 2006
S
Santhera Pharmaceuticals
Biotech · Growth, 2004
B
Basilea Pharmaceutica
Biotech · Growth, 2000
Notable Exits
CompanyTypeYearValue / Acquirer
AM PharmaAcquisition2023$1.75B
Addex TherapeuticsIPO2010—
Santhera PharmaceuticalsIPO2010—
ESBATechAcquisition2009—
Basilea PharmaceuticaIPO2004—
ActelionIPO1997—
Frequently Asked Questions
BioMedPartners focuses on Series A, Series B, Series C+ stage investments.